Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06905197 · ClinicalTrials.gov registry record · Phase 1
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 5
- Study locations
NCT06905197: Recruiting Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Dizal Pharmaceuticals.
NCT06905197 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Dizal Pharmaceuticals. The registered enrollment target is 140 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06905197, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Dizal Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
Primary Outcome
Number of participants with Dose-limiting Toxicities (DLTs)
Conditions Studied
Interventions
- DRUG DZD6008
- DRUG Sunvozertinib
Study Locations (5)
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Herbert Irving Comprehensive Cancer Center - New York
New South Wales
- Blacktown Hospital - Blacktown
- Chris O'Brien Lifehouse - Camperdown
Virginia
- Virginia Cancer Specialist (NEXT Oncology-Virginia) - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06905197 shows while recruiting
NCT06905197 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which DZD6008 is the first listed.
NCT06905197 lists 5 locations in 3 states (New York, New South Wales, Virginia).
Frequently Asked Questions
What is clinical trial NCT06905197 about?
NCT06905197 is a clinical study titled "A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)". This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.
What is the current status of trial NCT06905197?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2025-05-13. Estimated completion is 2028-12.
What conditions does trial NCT06905197 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06905197?
The interventions under investigation include: DZD6008 (DRUG), Sunvozertinib (DRUG).
Who is sponsoring clinical trial NCT06905197?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06905197 being conducted?
This trial has 5 study locations across New York, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06905197's enrollment target sits among peer trials
140 206th of 454 higher than 247 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI